Cost cuts help Biogen improve financial bottom line
Biogen delivered a better-than-expected third quarter and hiked its 2022 forecast, as cost cutting continued to help the drug maker balance sliding sales.
Read More
biogen
Job cuts at Biogen, which has big RTP presence, help drug giant reduce costs 40%
Cost cutting helped Biogen beat second-quarter expectations soundly even as revenue slid and sales of the drugmaker’s controversial Alzheimer’s treatment collapsed.
Read More
Biogen shares drop after revenue, earnings forecast fall short of Street expectations
Biogen expects “minimal” revenue this year from its Alzheimer’s treatment initially hailed as potentially a breakthrough drug, but one with an eye-popping price tag that drew immediate criticism from doctors and patient advocates.
Read More
Biogen stock surges 10% on report of possible sale
RESEARCH TRIANGLE PARK – Shares in Biogen, the drug giant that has a major presence in RTP, surged Wednesday when rumors emerged that the company was exploring a possible acquisition by Samsung Biologics. However, the report was deined by the South Korea-based company. Shares were off some 5% in...
Read More
Are layoffs about to hit Biogen workforce? Drug giant won’t comment
Drug giant Biogen is not commenting on information provided to WRAL TechWire saying that the company is planning to lay off “hundreds of workers.”
Read More
Ground breaking: Biogen’s $200M RTP gene therapy facility means new jobs
Biogen will break ground today for a gene therapy manufacturing plant at its growing RTP campus.
Read More
Biogen discloses new Azlheimer’s drug brings in only $300,000, makes layoffs in Raleigh
A new Alzheimer’s drug from Biogen brought in only $300,000 in sales during its first full quarter on the market, extending a slow debut complicated by coverage questions and doctor concerns. The news came Wednesday as Biogen also confirmed making layoffs among its patient support staff in Raleigh.
Read More
Biogen making layoffs in Raleigh, cites delay in Alzheimer’s drug access, new tech
Drug giant Biogen is making layoffs among its patient support staff in Raleigh, citing delays in patient access to its recently approved Alzheimer’s drug as well as advances in what it calls “new technologies.”
Read More
Biogen Alzheimer’s drug debate: ‘It’s the billion-dollar question: What’s going on here?
At its core, the controversy about Biogen’s Aduhelm raises a fundamental question: Did the FDA approve a drug that doesn’t help people – and if so, why?
Read More
